CT
Celea TherapeuticsClinical-stage biotech developing deupirfenidone, a deuterated pirfenidone-derived drug for idiopathic pulmonary fibrosis, spun out of PureTech Health.
4 Pulse stories
TB
Triveni BioTriveni Bio develops genetics-informed antibody and bispecific therapeutics for immunological and inflammatory diseases.
2 Pulse stories
Total Raised
$180M
$272M
Celea TherapeuticsTriveni Bio
Last ValuationNot disclosed
Biotech
Sector
Biotech
2025
Founded
2023
Boston, MA
HQ
Waltham, Massachusetts
Private
Status
Private
Celea Therapeutics investors
RA Capital ManagementLeaps by BayerPureTech Health
Triveni Bio investors
Atlas VentureCormorant Asset ManagementAscenta CapitalJanus Henderson InvestorsDeep Track CapitalOrbiMedViking Global InvestorsFidelity Management & Research
Data from Value Add Pulse coverage and company research — see the full threads for Celea Therapeutics and Triveni Bio.